Study targets NSAID use

Focus is on susceptibility to postop CME in eyes with pre-existing vitreoretinal conditions 

This article was reviewed by Jan Gärdin, MD, and Björn Johansson, MD, PhD.

A retrospective, population-based, controlled study analyzing data from an unselected patient population undergoing cataract surgery found that neither the need for unplanned postoperative visits for complications nor the incidence of visually disturbing cystoid macular edema (CME) was significantly reduced by adding a topical NSAID to postoperative topical steroid treatment.

The research, however, did highlight increased susceptibility to postoperative CME in eyes with pre-existing vitreoretinal conditions.

“Results of randomized controlled trials indicate that the occurrence of CME is reduced in eyes treated with an NSAID, either in combination with a steroid or alone,” said Jan Gärdin, MD, resident, Department of Ophthalmology, Linköping University, Linköping, Sweden.

Dr. Gärdin noted that it is sometimes difficult to relate study results to what is perceived as clinical reality.

“In our investigator-initiated study including a large number of eyes from an unselected patient population, we were not able to demonstrate a clear benefit for the cohort that received combination therapy,” he added.

Björn Johansson, MD, PhD, co-investigator in the study and associate professor of ophthalmology, Linköping University, said the study has highlighted some interesting treatment options.

“Although randomized controlled studies remain the gold standard for evaluating the efficacy of new treatments, adequately designed and conducted clinical studies such as our retrospective population-based trial are an important complement to clarify how medical and surgical treatments are used in an optimal fashion in unselected clinical populations,” he said. “The findings from such studies may have both medical and economic impact.”

Related: Large population-based study questions value of routine NSAID use after cataract surgery 

The population-based controlled study analyzed data from two groups of consecutive patients operated on in the eye clinics of Vrinnevi Hospital, Norrköping, Sweden and Linköping University Hospital, Linköping, Sweden. The two facilities are in the same county, publicly financed, and under the same regional clinical center, and they use the same electronic patient record system. However, they use different standard protocols for controlling postoperative inflammation, Dr. Gärdin explained.

At Vrinnevi Hospital, patients are treated for three weeks after surgery with a topical steroid and a topical NSAID, each given three times daily. Patients undergoing cataract surgery at the eye clinic of Linköping University Hospital are treated only with a tapering dose of a steroid for three weeks.

Using the electronic medical record system and beginning the search in January 2015, investigators identified a total of 500 consecutive eyes from each hospital. The selected eyes were from patients aged 20 years and older.

Patients were excluded if they had posterior capsular rupture and/or zonular damage preventing in-the-bag IOL placement, deviation from the center’s standard protocol for topical anti-inflammatory treatment, or a pre-existing ocular malformation. Data were extracted on baseline characteristics and unplanned postoperative visits within six months after surgery.

Related: Controlled trial identifies limited benefits of adjunctive NSAIDs

The two study groups were balanced with respect to gender and right/left eye distribution. Each group had a predominance of females over males and included a majority of right eyes.
The mean age was about 75 years and similar in the two study groups. Mean logMAR BCDVA was also similar in the two groups preoperatively.

A review of preoperative ocular comorbidities showed the percentage of eyes with pseudoexfoliation was higher in the group that received the steroid alone compared with those treated with combination therapy. The group receiving combination therapy had higher percentages of eyes with an epiretinal membrane (ERM) and with diabetic maculopathy or retinopathy. The number of patients with diabetes and with age-related macular degeneration was similar in the two groups.

Though a higher rate of unplanned postoperative visits was found for the group receiving combination treatment than among eyes treated only with a steroid, the difference was not statistically significant (16.6% versus 12.6%; p = 0.073). CME occurred in eight eyes (1.6%) in the combination treatment group and in six eyes (1.4%) treated with steroid alone.

“The overall incidence of CME in our total cohort was 1.2%, but when patients with diabetes or an ERM were removed, the overall incidence of CME decreased to 0.8%,” Dr. Gärdin pointed out.
Clinically significant CME occurred in 2.9% of eyes in patients with diabetes mellitus and in 8.2% of eyes with an ERM.

“The incidence of clinically significant CME among patients in our study who had an ERM was 10-fold higher than in our patients without diabetes and no ERM, indicating patients with an ERM had a drastically increased risk,” Dr. Gärdin concluded.

Read more by Cheryl Guttman Krader